Eli Lilly and Novo Nordisk have agreed pricing deals for GLP-1RA brands, a pivotal moment in the obesity treatment market.

Editor's note: this interview was originally published on BioPharmInternational.com.

Q3 2025 Management View CEO Stephen Silvestro reported a strong third quarter with revenues increasing 22% year-over-year to ...

Q3 2025 Earnings Call November 6, 2025 4:30 PM ESTCompany ParticipantsStephen Silvestro - President & CEOEdward Stelmakh ...

Alvotech and Advanz Pharma have announced the receipt of marketing authorisations from the MHRA for all four formulations of ...

Market opportunities lie in modernizing software development and validation approaches, emphasizing agility and continuous validation to meet changing needs, while ensuring compliance with FDA ...

Sonoma Pharmaceuticals Inc. (Nasdaq: SNOA) reported record revenue and a lower net loss for the second quarter of its fiscal year.

The US Food and Drug Administration-approved Marie system promises human-centred care, advanced technology and lower costs.

This company runs the financial plumbing behind India’s investment ecosystem, earning recurring fees from mutual funds, ...

The Authority will provide grants to establish the centres, the GBU will be responsible for setting them up and managing operations, said officials ...

NeuroDiscovery AI offers a specialised AI platform for neurology that helps doctors diagnose brain diseases and ...

Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced its successful participation in the ...